Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.52 |
| ▸ | MEN1 | O00255 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 4/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1145997 | 0.78 | KDM4E (0.37) | — | |
| SCHEMBL27842457 | 0.76 | KMT2A (0.55) | KMT2AMEN1ALDH1A1TSHRMAPT | |
| SCHEMBL4156875 | 0.73 | KMT2A (0.63) | KMT2AMEN1ALDH1A1TSHRMAPT | |
| SCHEMBL29035960 | 0.73 | KMT2A (0.60) | KMT2AMEN1ALDH1A1TSHRMAPT | |
| SCHEMBL4745228 | 0.73 | ALDH1A1 (0.41) | KMT2AMEN1ALDH1A1TSHRMAPT | |
| SCHEMBL31254284 | 0.72 | KMT2A (0.58) | KMT2AMEN1ALDH1A1TSHRMAPT | |
| SCHEMBL29638283 | 0.72 | KMT2A (0.58) | KMT2AMEN1ALDH1A1TSHRMAPT | |
| SCHEMBL28647868 | 0.72 | KMT2A (0.61) | KMT2AMEN1ALDH1A1TSHRMAPT | |
| SCHEMBL651847 | 0.72 | KMT2A (0.58) | KMT2AMEN1ALDH1A1TSHRMAPT | |
| SCHEMBL2102471 | 0.72 | KMT2A (0.58) | KMT2AMEN1ALDH1A1TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6908922-B2 | Anticholesterol agents; cardiovascular disorders | LES LABORATOIRES SERVIER (FR) | 2005-06-21 | — | — | US | disclosed |
| US-6780868-B2 | TREATMENT OF MYOCARDIAL OR PERIPHERAL ISCHAEMIA, CARDIAC INSUFFICIENCY OR PULMONARY ARTERIAL HYPERTENSION | LES LABORATOIRES SERVIER (FR) | 2004-08-24 | — | — | US | disclosed |
| US-20030225105-A1 | New linear cyclic ureas | PEGLION JEAN-LOUIS (FR) | 2003-12-04 | — | — | US | disclosed |
| US-20030191132-A1 | New linear cyclic ureas | PEGLION JEAN-LOUIS (FR) | 2003-10-09 | — | — | US | disclosed |
| US-6566364-B2 | Isomers, hydrates, solvates and addition salts in treatment of endothelial dysfunction disease such as atherosclerosis, dyslipidaemia; antidiabetic agents; heart transplantation; inhibition of nitrogen monoxide synthase and oxidative stress | LES LABORATOIRES SERVIER (FR) | 2003-05-20 | — | — | US | disclosed |
| US-20010009911-A1 | New linear or cyclic ureas | LES LABORATOIRES SERVIER (FR) | 2001-07-26 | — | — | US | disclosed |
| EP-1113014-A1 | Linear or cyclic ureas, a process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010009911-A1 | New linear or cyclic ureas | GUCY1B1, UACA, LIPG | KMT2A 4503/4885MEN1 4125/4885ALDH1A1 424/4885 |
| US-20030191132-A1 | New linear cyclic ureas | GUCY1B1, UACA, GUCY1A1 | KMT2A 4267/4885MEN1 4060/4885ALDH1A1 367/4885 |
| US-20030225105-A1 | New linear cyclic ureas | GUCY1B1, UACA, GUCY1A1 | KMT2A 4267/4885MEN1 4060/4885ALDH1A1 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.